INTERSTITIAL LUNG DISEASE
Adverse reaction reported in 11,890 FDA reports across 17 drugs.
11,890
Total Reports
17
Drugs Involved
Pembrolizumab
Most Reported Drug
Drugs Associated with INTERSTITIAL LUNG DISEASE
Drugs where "INTERSTITIAL LUNG DISEASE" was reported as an adverse event.
| # | Drug | Reports | % of Total |
|---|---|---|---|
| 1 | Pembrolizumab | 2,434 | |
| 2 | Nivolumab | 1,614 | |
| 3 | Fam-Trastuzumab Deruxtecan-Nxki | 982 | |
| 4 | Pemetrexed Disodium | 884 | |
| 5 | Atezolizumab | 810 | |
| 6 | Vincristine | 680 | |
| 7 | Lenvatinib | 651 | |
| 8 | Osimertinib | 579 | |
| 9 | Durvalumab | 464 | |
| 10 | Pemetrexed | 427 | |
| 11 | Gefitinib | 420 | |
| 12 | Olaparib | 378 | |
| 13 | Panitumumab | 375 | |
| 14 | Bicalutamide | 365 | |
| 15 | Abemaciclib | 354 | |
| 16 | Daptomycin | 251 | |
| 17 | Bleomycin | 222 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. The presence of a drug in this list does not mean the drug caused interstitial lung disease. Always consult your healthcare provider.